menu
    • menu
    [{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Sabal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Athena Bioscience \/ Athena Bioscience","highestDevelopmentStatusID":"15","companyTruncated":"Athena Bioscience \/ Athena Bioscience"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Clonidine","moa":"Adrenergic receptor alpha-2","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Athena Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tramadol Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Athena Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athena Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Athena Bioscience","sponsor":"Tris Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Athena Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Athena Bioscience \/ Athena Bioscience","highestDevelopmentStatusID":"1","companyTruncated":"Athena Bioscience \/ Athena Bioscience"}]

    Find Clinical Drug Pipeline Developments & Deals by Athena Bioscience

    Menu

    Athena Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Athena Bioscience

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            Athena Bioscience

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clonidine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Athena Bioscience Announces Launch of Nexiclon™ XR, the Only Once-Daily Clonidine Extended-Release Tablets f...

                            Details : The launch of Nexiclon XR, the only once-daily clonidine extended-release tablets is based on Tris's LiquiXR drug delivery technology, which has led to the development of multiple first-in-category products indicated for treatment of hypertension.

                            Product Name : Nexiclon

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2022

                            Lead Product(s) : Clonidine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Athena Bioscience

                            U.S.A arrow
                            PREP
                            Not Confirmed

                            Athena Bioscience

                            U.S.A arrow
                            PREP
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clonidine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Sabal Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sabal Therapeutics Announces Sales and Marketing Agreement to Promote Athena Bioscience Cardiovascular Product...

                            Details : This partnership aligns perfectly with Sabal’s mission to support commercial launch for two products, Nexiclon™ XR and Fibricor®, by helping them deliver their products to physicians and patients who need them.

                            Product Name : Nexiclon XR

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 22, 2022

                            Lead Product(s) : Clonidine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Sabal Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Athena Bioscience

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Athena Bioscience

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Undisclosed

                            Recipient : Tris Pharma Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Tris Pharma, Athena Bioscience Enter Exclusive License Agreement

                            Details : The licensed product upon launch, will be the only once-daily formulation containing an established Active Pharmaceutical Ingredient (API), which physicians can optionally prescribe alone or concomitantly with other antihypertensive agents to pursue desi...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 22, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Tris Pharma Inc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Athena Bioscience

                            U.S.A arrow
                            OPRD
                            Not Confirmed

                            Athena Bioscience

                            U.S.A arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves Athena Bioscience's New Drug Application (NDA) for QDOLO™ (tramadol hydrochloride) Oral So...

                            Details : USFDA has approved QDOLO™ (tramadol hydrochloride) Oral Solution 5mg/1mL C-IV, an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

                            Product Name : Qdolo

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 08, 2020

                            Lead Product(s) : Tramadol Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth